Researchers from Engrail Therapeutics Inc. recently described the pharmacological characterization of ENX-105, a new class of molecule that combines 5-HT1A/2A receptor agonism with D2/3 receptor antagonism, to be used for its antianhedonic and antipsychotic effects.